Once a prescription is written – just one part of the brand adoption challenge – pharmaceutical manufacturers are limited in their ability to influence patient compliance and persistence. For years, pharma manufacturers have struggled to influence change in the 20-30 percent of prescriptions that never get filled and the estimated 50 percent of patients who do not take their medication as directed, if at all. Manufacturers need patient education and engagement resources that can influence patient behavior, a process we describe as outcomes advocacy.
Where and when in the patient lifecycle is the optimal level of patient intervention and care coordination that delivers better outcomes and high value? Answering this question successfully will become increasingly important to pharmaceutical manufacturers, including their brand teams, as outcomes-based contracts with payers proliferate and mature.
“Insurance companies thrive on minimizing risk; health insurers are no exception. Legacy tactics include prior authorization, step edits and formulary restrictions. The latest strategy has arrived with the advent of the outcomes-based contract, where reimbursement for a drug is based in part on observed outcomes of the drug’s use in a specific patient population. These contracts give insurers a new tool to minimize their financial risk if a therapy fails to generate the expected patient outcome. These contracts also provide the pharma manufacturer the opportunity to deliver on the brand’s promise.” – Vickie Andros, PharmD, Director of Clinical Services and Jake Caines, Senior Director of Commercial Strategy and Performance
Learn how the Curant Health Patient Education & Engagement Resource (PEER) Model supports improvements in outcomes advocacy through proven care management techniques, differentiated outcomes and actionable insights.
For more information, contact us at Peerprogram@curanthealth.com.